SCHEMBL3069036

SCHEMBL3069036

O=Cc1c(Cl)cc(C(=O)O)cc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.58
TPMT P51580 4/20 0.50
TSHR P16473 2/20 0.50
ALDH1A1 P00352 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SRD5A2 P31213 1/20 0.44
HCAR1 Q9BXC0 1/20 0.43
PLAU P00749 1/20 0.43
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41
UNG P13051 1/20 0.41
LCK P06239 1/20 0.40
FYN P06241 1/20 0.40
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15322344 0.86 TTR (0.48) TTRTPMTTSHRALDH1A1SRD5A2
SCHEMBL15323116 0.86 TTR (0.48) TTRTPMTTSHRALDH1A1TDP1
SCHEMBL8979372 0.82 ALDH1A1 (0.44) TTRTPMTTSHRALDH1A1TDP1
SCHEMBL15357977 0.82 TTR (0.44) TTRTPMTTSHRSRD5A2HCAR1
SCHEMBL29160651 0.80 TTR (0.56) TTRTPMTTSHRALDH1A1TDP1
SCHEMBL11556678 0.75 TTR (0.76) TTRTPMTTSHRALDH1A1TDP1
SCHEMBL7263572 0.75 TTR (0.68) TTRTPMTTSHRALDH1A1TDP1
SCHEMBL15320957 0.75 ALDH1A1 (0.48) TPMTTSHRALDH1A1TDP1MEN1
SCHEMBL31056230 0.75 TTR (0.67) TTRTPMTTSHRALDH1A1TDP1
SCHEMBL7541938 0.74 ALDH1A1 (0.43) TTRTPMTTSHRALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104341316-A Diarylamide type derivatives, preparing method thereof, pharmaceutical compositions of the derivatives and uses of the derivatives SHANGHAI INST MATERIA MEDICA 2015-02-11 CN disclosed
US-8889722-B2 Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor SHIONOGI & CO., LTD. (JP) 2014-11-18 US disclosed
US-8889722-B2 Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor SHIONOGI & CO., LTD. (JP) 2014-11-18 US disclosed
US-8889722-B2 Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor SHIONOGI & CO., LTD. (JP) 2014-11-18 US disclosed
EP-2184279-B1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF SHIONOGI & CO (JP) 2014-11-12 EP disclosed
US-8530668-B2 Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor SHIONOGI & CO., LTD. (JP) 2013-09-10 US disclosed
US-8530668-B2 Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor SHIONOGI & CO., LTD. (JP) 2013-09-10 US disclosed
US-8530668-B2 Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor SHIONOGI & CO., LTD. (JP) 2013-09-10 US disclosed
US-20130217885-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR SHIONOGI & CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217885-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR SHIONOGI & CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217885-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR SHIONOGI & CO., LTD. (JP) 2013-08-22 US disclosed
US-20100267783-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) 2010-10-21 US disclosed
US-20100267783-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) 2010-10-21 US disclosed
US-20100267783-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) 2010-10-21 US disclosed
EP-2184279-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF Shionogi&Co., Ltd. (JP) 2010-05-12 EP disclosed
EP-2184279-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF Shionogi&Co., Ltd. (JP) 2010-05-12 EP disclosed
EP-0604019-B1 N-Acetonylbenzamides and their use as fungicides ROHM & HAAS (US) 1996-05-08 EP disclosed
EP-0604019-A1 N-Acetonylbenzamides and their use as fungicides ROHM AND HAAS COMPANY (US) 1994-06-29 EP disclosed
US-5254584-A Controlling phytopathogens ROHM AND HAAS COMPANY (US) 1993-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267783-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR MPL, TEK, THPO TTR 1999/4885TPMT 2949/4885TSHR 98/4885
US-20130217885-A1 PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR MPL, TEK, THPO TTR 2016/4885TPMT 2863/4885TSHR 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.